Skip to main content
. 2020 Oct 14;47(11):8657–8668. doi: 10.1007/s11033-020-05908-3

Table 2.

Samples and sequences used in this study: each sample ID referrs to individual hepatitis patients

Sample ID Anti-HEV HEV RNA Accession number
IgM IgG In serum In feces
TH-hu-FJN + ND + MH427099
TH-hu-FNP + + + + MH427105
TH-hu-FYS + + + MH427098
TH-hu-FUD + + + MH427100
TH-hu-FKP + + + + MH427106
TH-hu-FSN + + + + MH427095
TH-hu-FOG + + + + MH427103
TH-hu-FTM + ND + + MH427096
TH-hu-FLR + + + MH427104
TH-hu-F40 + + + + MH427091
TH-hu-FPP - + + + MH427092
TH-hu-FKS + + + + MH427090
TH-hu-FSP + ND + + MH427097
TH-hu-F45-1 + ND + + KY232312, KY232313
TH-hu-FTK + + + MH427094
TH-hu-FTS + + + + MH427102
TH-hu-FVS + + + + MH427093
TH-hu-F47 + + + + MH427101

The anti-HEV, both IgM and IgG, were detected in the serum specimens. The HEV RNA was detected from serum and fecal samples. HEV in the serum and fecal specimens from patient TH-hu-F45-1 was chosen to perform genome sequencing. The accession number KY232312 and KY232313 refer to the HEV from serum and feces, respectively

ND not done